Liquid Biopsy Market Overview
The liquid biopsy market is rapidly growing, reflecting the increasing demand for non-invasive cancer diagnostics. As cancer rates continue to rise globally, early detection and monitoring of cancer have become essential in improving patient outcomes. Traditionally, tissue biopsy has been the gold standard for cancer diagnosis. However, it is invasive, painful, and often associated with risks and complications. This has led to the rise of liquid biopsy, a non-invasive alternative using blood samples or other bodily fluids like plasma, urine, and saliva for cancer detection.
The liquid biopsy market is projected to expand from USD 3.72 billion in 2024 to USD 15.45 billion by 2033, growing at a CAGR of 17.14% between 2025 and 2033. This rapid growth is driven by the increasing prevalence of cancer, technological advancements, and a significant shift toward personalized medicine and non-invasive diagnostic methods.
Request a free sample copy of the report:htt